Strata Oncology partnered with UW Health to integrated its next generation sequencing tumor profiling test into the health system's Epic EHR. Being able to order the test and see its results from within the EHR will help UW clinicians more efficiently leverage genomic findings into their precision oncology treatment plans.
Ochsner Health added a tool to its Epic EHR that allows physicians to seamlessly order genomics tests and view results within the EHR. The integration will allow physicians to provide more personalized and effective care now that they can have a single view of their patients’ genomic and clinical data in one place. The news comes two months after MU Health Care added a similar tool into its Oracle Cerner EHR.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The Covid-19 pandemic has brought a laser focus to the critical and immediate need for next-generation sequencing tools that can generate invaluable data for not only identifying emerging variants but for understanding the functional and epidemiological consequences of variant-specific mutations.
Illumina originally spun off Grail in early 2017. Grail plans to launch its test for early detection of cancers, Galleri, next year. Illumina already owns 14.5% of the company, which it started in 2016.
By harnessing the combined power of NGS, machine learning and the dynamic nature of RNA we’re able to accurately measure the dynamic immune response and capture a more comprehensive picture of what’s happening at the site of the solid tumor.
ArcherDX had filed with the SEC earlier this month for a $100 million initial public offering. The two companies said combining would enable cancer patients to access a variety of testing products and services from one source.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Under the decision, Medicare patients with inherited cancer mutations such as BRCA will receive coverage for NGS testing. Drugs that treat BRCA-mutated breast and ovarian cancers include AstraZeneca's Lynparza and Pfizer's Talzenna.
The companies said the deal, financial terms of which were not disclosed, would enable expansion of next-generation sequencing capabilities in rare diseases.
The company filed for FDA approval of the FoundationOne Liquid test at the end of December. Data from a clinical trial presented at an October conference showed the test had a strong ability to detect a genetic driver mutation in lung cancer.
Separately, the next-generation sequencing manufacturer will also work with Genomics England to sequence up to 300,000 people over the next five years.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The Rochester, Minnesota-based healthcare system and San Mateo, California-based population genomics company plan to launch the study in the next few weeks.
The Federal Trade Commission had accused Illumina of seeking to monopolize the market for next-generation sequencing in its effort to acquire Pacific Biosciences, originally announced in November 2018.
Federal regulators said they would seek to block the acquisition deal amid concerns that Illumina was seeking to eliminate PacBio as a competitor in the next-generation sequencing space.
The agency announced it had authorized Vela Diagnostics' Sentosa SQ HIV Genotyping Assay, designed to help healthcare providers tailor antiviral therapy based on the presence of viral resistance mutations.
The biotechnology product development company announced the launch of its Ion Torrent Genexus System at the Association for Molecular Pathology's annual meeting.